Can replacement and short-chain PFAS disrupt endocrine, immune, and metabolic signaling?

Short-chain and replacement per- and polyfluoroalkyl substances (PFAS)—including perfluorobutanoic acid (PFBA), perfluoropentanoic acid (PFPeA), and GenX (HFPO-DA)—were introduced to replace legacy long-chain compounds. However, current toxicological and experimental evidence demonstrates that these replacements actively disrupt critical endocrine, immune, and metabolic signaling pathways.

Endocrine and metabolic disruption

• Nuclear receptor activation: Short-chain and replacement PFAS act as potent nuclear receptor agonists. PFBA directly binds and activates estrogen-related receptor γ (ERRγ) to modulate estrogenic signaling. GenX and PFBA also serve as agonists for peroxisome proliferator-activated receptors alpha and gamma (PPARα/γ), which disrupts hepatic lipid handling, fatty acid transport, and peroxisomal beta-oxidation.
• Hormonal and glycemic alteration: In vivo models of PFBA exposure show thyroid endocrine disruption, characterized by decreased total and free thyroxine (T4) levels and increased relative thyroid weight. Additionally, PFPeA alters glycemic regulation and hepatic metabolic networks by perturbing PPAR, AMPK, FoxO, and PI3K-Akt signaling pathways.

Immune signaling alteration

• Pro-inflammatory pathway activation: PFBA drives PPAR-independent inflammatory cascades. Specifically, it activates the Toll-like receptor (TLR)–NF-κB/MAPK pathway, which significantly upregulates the expression of key pro-inflammatory cytokines, including interleukin-8 (IL-8) and tumor necrosis factor-alpha (TNFα).
• Innate immune suppression: In contrast, GenX suppresses innate immune defenses. In vivo studies show that GenX dampens acute inflammatory responses by suppressing the critical neutrophil chemokines CXCL1 and CXCL2, which directly reduces necessary neutrophil recruitment.

Bottom line

• Replacement and short-chain PFAS (PFBA, PFPeA, and GenX) are biologically active agents that disrupt endocrine, metabolic, and immune signaling. They exert these effects through direct nuclear receptor binding (ERRγ and PPARα/γ) and downstream cascade perturbations (including TLR-NF-κB, CXCL1/2, and AMPK/FoxO pathways), resulting in altered thyroid hormone levels, lipid dysregulation, and altered immune responses.